PROCEPT BioRobotics (PRCT)
(Real Time Quote from BATS)
$89.27 USD
+3.36 (3.91%)
Updated Nov 15, 2024 02:44 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for PROCEPT BioRobotics Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 136 | 75 | 34 | 8 | NA |
Cost Of Goods | 65 | 38 | 19 | 9 | NA |
Gross Profit | 71 | 37 | 16 | -1 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 180 | 118 | 70 | 47 | 0 |
Income After Depreciation & Amortization | -109 | -81 | -54 | -48 | 0 |
Non-Operating Income | 7 | -1 | 0 | 0 | NA |
Interest Expense | 4 | 5 | 6 | 5 | NA |
Pretax Income | -106 | -87 | -60 | -53 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -106 | -87 | -60 | -53 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -106 | -87 | -60 | -53 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -105 | -78 | -51 | -45 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 3 | 3 | NA |
Income After Depreciation & Amortization | -109 | -81 | -54 | -48 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 47.26 | 44.40 | 16.48 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.24 | -1.89 | -3.63 | NA | NA |
Diluted Net EPS (GAAP) | -2.24 | -1.96 | -3.63 | NA | NA |
Fiscal Year end for PROCEPT BioRobotics Corporation falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 58.37 | 53.35 | 44.54 | 43.58 | 35.10 |
Cost Of Goods | 21.46 | 21.87 | 19.51 | 22.33 | 16.23 |
Gross Profit | 36.91 | 31.48 | 25.03 | 21.25 | 18.87 |
SG&A, R&D, and Dept/Amort Expenses | 59.34 | 58.31 | 52.68 | 50.82 | 44.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.43 | -26.83 | -27.65 | -29.57 | -25.61 |
Non-Operating Income | 2.59 | 2.23 | 2.74 | 3.18 | 2.01 |
Interest Expense | 1.14 | 1.03 | 1.05 | 1.13 | 1.02 |
Pretax Income | -20.97 | -25.63 | -25.96 | -27.51 | -24.62 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -20.97 | -25.63 | -25.96 | -27.51 | -24.62 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -20.97 | -25.63 | -25.96 | -27.51 | -24.62 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 52.01 | 51.62 | 51.01 | 50.59 | 48.31 |
Diluted EPS Before Non-Recurring Items | -0.40 | -0.50 | -0.51 | -0.54 | -0.51 |
Diluted Net EPS (GAAP) | -0.40 | -0.50 | -0.51 | -0.54 | -0.51 |